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Abstract 
 
Rifampicin is an effective antibiotic against mycobacterial and other bacterial infections, 
but resistance readily emerges in laboratory and clinical settings.  We screened 
Escherichia coli for rifampicin resistance and identified numerous mutations to the gene 
encoding the β chain of RNA polymerase (rpoB), including an unusual nine nucleotide 
deletion mutation.  Structural modeling of the deletion mutant indicates locations of 
potential steric clashes with rifampicin.  Sequence conservation in the region near the 
deletion mutation suggests a similar mutation may also confer resistance during the 
treatment of tuberculosis. 
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Introduction 
Rifampicin (RIF) is a member of rifamycin antibiotics used in the treatment of 
tuberculosis and other bacterial infections [Sensi, 1983].  It targets bacterial RNA 
polymerases by binding near the polymerase active site and inhibiting the elongation of 
nascent mRNA [Campbell et al., 2001].  The catalytic core of bacterial RNA polymerases 
consists of α2, β, β´, and ω chains, and rifampicin binds to a pocket formed by the β chain 
(Fig. 1A) [Campbell et al., 2001; Molodtsov et al., 2013]. Although rifampicin binds in 
the RNA tract, many of the residues in the rifampicin binding pocket do not directly 
contact the RNA.  Numerous mutations in the RNA polymerase β chain confer rifampicin 
resistance (RIFR) in Escherichia coli and Mycobacterium tuberculosis [Xu et al., 2005; 
Makiela-Dzbenska et al., 2011; Zhou et al., 2013; Jin, and Gross, 1989; Sandgren et al., 
2009; Barrick et al., 2010].  These mutations are clustered in four regions of RNA 
polymerase β, termed RIF resistance-determining regions (RRDRs) N, I, II, and III 
(Molodtsov et al. 2016).  Crystal structures of rifampicin bound to RNA polymerases of 
Thermus aquaticus and E. coli show that all four RRDRs consist of residues located 
within ~10 Å of rifampicin [Campbell et al., 2001; Molodtsov et al., 2013].  RIFR 
mutations and structural studies have provided detailed information on how M. 
tuberculosis and other bacteria evade the antibiotic action of rifampicin and other 
rifamycins [Artsimovitch et al., 2005; Molodtsov et al., 2017]. 
 In this study, we selected E. coli for rifampicin resistance in the absence of 
mutagens and sequenced a region of RNA polymerase β chain encompassing RRDRs I, 
II, and III to identify new RIFR mutations.  Nonpathogenic E. coli serves as an excellent 
experimental system to probe rifampicin resistance because of its ease of handling in the 
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laboratory in contrast to M. tuberculosis, and there exists an abundance of structural and 
biochemical information on its RNA polymerase [Molodtsov et al., 2013; Campbell et al., 
2001; Kang et al., 2017; Gill, and Garcia, 2011].  While most of the E. coli mutants 
contained previously characterized mutations, we identified a new mutation located in 
RRDR-I, an unusual in-frame deletion that did not result in misfolding of RNA 
polymerase.   
 
Results & Discussion 
Rifampicin resistance in E. coli.  Selection of E. coli K-12 MG1655 laboratory strain 
bacteria on LB plates containing rifampicin readily produced a large and variable number 
of rifampicin-resistant clones (results not shown).  The number of RIFR colonies and the 
total live bacteria in each of 64 cultures were counted and used to compute the mutation 
rate from Luria-Delbrück fluctuation tests [Luria, and Delbrück, 1943; Gillet-Markowska 
et al., 2015; Ycart, and Veziris, 2014].  We estimate the mutation rate of the MG1655 
strain at 2.0 x 10-9, which is in general agreement with other studies on E. coli lab strains 
and rifampicin-resistance [Bjedov et al., 2003; Galán et al., 2007] but lower than rates 
from clinical isolates  [Baquero et al., 2004].   
Identity of RIF-resistance mutations.  The chromosomal rpoB gene fragment containing 
the region that codes for residues 473-720 of the β chain of RNA polymerase was directly 
amplified from RIFR colonies using the polymerase chain reaction, resulting in a 744 base 
pair band (results not shown).  This section of E. coli RNA polymerase encompasses the 
rifampicin-binding site and RIF resistance-determining region, including clusters I 
(residues 507-533), II (residues 563-572), and III (residue 687), but not the N-terminal 
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cluster (residue 146).  Sequencing of PCR products revealed 16 different mutations in 
clusters I and II (Table 1).  All but one of the cluster I mutations have previously been 
reported in rifampicin-resistant E. coli mutants.  The 9 bp deletion had not been 
previously reported, to our knowledge, but is similar to a previously characterized 
deletion that replaces 507-GSSQL-511 with V [Jin, and Gross, 1989].  The deleted 
sequence (nucleotides 1517-1525 in the rpoB open reading frame, TCGGTTCCA) 
contained no obviously unusual features (e.g. A-T rich, long tracts of single nucleotides, 
self-annealing sequences).  Mutations at I572 and S574 in cluster II have also previously 
been identified in RIF-resistant E. coli clones [Jin, and Gross, 1989; Zhou et al., 2013; 
Makiela-Dzbenska et al., 2011; Sandgren et al., 2009; Barrick et al., 2010].  Several of 
these mutations occurred in positions that increased transcript deletions (Q513) or 
decreased transcriptional elongation slippage (D516 and I572) by E. coli RNA 
polymerase [Zhou et al., 2013].   
 Two of the clones (out of 81 total) contained no mutations to the coding region 
for residues 473-720.  It is possible that these contained a mutation to the N-terminal 
cluster of rpoB or other regions of genes encoding RNA polymerase.  Alternatively, 
mutations of other E. coli genes could lead to rifampicin secretion or breakdown could 
also result in resistance.  We did not subject these clones to genome sequencing to 
determine if this was the case.  Of the sequenced clones, the H526Y mutant was the most 
abundant (29/81).  The mutations of nucleotides 1546 (GAC to AAC; D516N), 1547 
(GAC to GGC; D516G), 1576 (CAC to TAC; H526Y), and 1592 (TCC to TTC; S531F), 
were the only transition mutations observed (35/81).   
Relationship of mutations to the rifampicin binding site in RNA polymerase.   
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Rifampicin-resistant mutants were mostly clustered to the rifampicin binding site in RNA 
polymerase β (Fig. 1B).  Several of the residues where mutations occur are adjacent to 
where rifampicin binds (Q513, D516, H526, S531, I572).  Mutations to these first shell 
residues are expected to alter the shape and/or chemical characteristics of the rifampicin 
binding site without substantially affecting the structure or function of RNA polymerase.  
According to the RNA polymerase-rifampicin complex structure [Molodtsov et al., 
2013], the serine 512 and 574 side chains do not contact rifampicin, but point towards the 
interior of the protein.  Mutation to a larger tyrosine at residue S512 or at S574 would 
require a change to the backbone structure, leading to possible changes in the rifampicin 
binding surface.   
Unusual in-frame deletion near rifampicin binding site.   
The deletion of nine base pairs (1517-1525; Δ9) from the rpoB gene changes 506-FGSS-
509 to C506.  Because RNA polymerase is essential to the survival and growth of E. coli, 
we concluded that the Δ9 mutation did not create a non-functional protein and that the 
folding and structure of the enzyme was largely retained.  In wild-type RNA polymerase, 
residues 506-509 reside at the end of an α-helix adjacent to the rifampicin binding site 
(Fig. 1B and 2A).  However, none of the residues contact rifampicin in the crystal 
structure.   
To understand the impact of the three-residue deletion on the structure of RNA 
polymerase, the translated protein sequence from the Δ9 mutant of rpoB was threaded 
into known crystal structures of E. coli RNA polymerase using Iterative Threading 
ASSEmbly Refinement (I-TASSER; [Yang et al., 2015]).  The Δ9 mutant model with the 
highest confidence score (C-Score of 1.65) produced by I-TASSER was highly similar to 
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known E. coli RNA polymerase crystal structures with identical secondary structural 
elements and a similar rifampicin binding site (Fig. 2A).  The 506-FGSS-509 sequence 
lies at the C-terminal end of an α helix pointing to where rifampicin binds, with glycine 
507 marking the end of the helix and the start of a loop.  The threaded model generated 
by I-TASSER indicates that shortening of the β chain sequence by three residues leads to 
the truncation of the α helix by one turn, but no substantial changes to the rest of the 
protein backbone.  A comparison of the RNA polymerase-rifampicin complex crystal 
structure (4KMU; [Molodtsov et al., 2013]) with the E. coli RNA polymerase elongation 
complex cryo-electron microscopy structure (5UPC; [Kang et al., 2017]) indicates that 
rifampicin inhibits RNA synthesis by blocking the path of the nascent RNA chain 
[McClure, and Cech, 1978; Campbell et al., 2001; Lin et al., 2017] and that residues 506-
509 of the β-chain lie near where the backbone of the transcript and template strand 
would lie in the transcriptional elongation complex (Fig. 2B).  The side chain of Q510 
(wild type numbering) in the Δ9 mutant makes contact with the RNA transcript backbone 
(Fig. 2B), but the clash could be alleviated by a rotamer change.  The observation that Δ9 
rpoB mutant formed a colony suggests that RNA polymerase activity is not substantially 
decreased by the unusual mutation.  
Although the Δ9 mutant does not result in large structural rearrangements near the 
mutation site, the sequence change does lead to rifampicin resistance.  The backbone of 
the next five residues after Δ9 mutation (QLSQF, numbered residues 510-514 in the wild 
type sequence) follows closely to the structure of full length, wild-type rpoB (Fig. 2C), 
but subtle structural changes in the Δ9 mutant model lead to steric clashes with 
rifampicin, particularly at Q513, F514, and I572 (wild type numbering).  The strong 
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overlap between rifampicin atoms and the Δ9 mutant model denoted by red disks in 
Figure 2C suggest that rifampicin may not bind well to the mutant without alterations to 
the protein surface.  One such change could be the rotations of side chains away from 
rifampicin if there is space.  The clashes between rifampicin and F514 and I572 can be 
resolved by rotamer changes in the two side chains.  However, the model indicates that 
the side chain of Q513 forms hydrogen bonds with the Q510 backbone and H526 side 
chains.  We note that the hydrogen bond between Q510-Q513 in the Δ9 mutant model is 
not present in wild type crystal structures (4KMU.pdb and 5UPC.pdb).  This interaction 
could prevent the Q513 side chain from swinging out of the way of rifampicin. Without 
an experimental atomic structure of this Δ9 mutant of RNA polymerase, we cannot be 
sure how this mutation confers rifampicin resistance, but we speculate that the subtle 
changes in structure immediately after residue 506, specifically the formation of a new 
backbone-side chain hydrogen bond, lock the β-chain into a conformation that has a 
lower binding affinity to rifampicin, thereby conferring resistance. 
Implications for rifampicin resistance in M. tuberculosis and other bacteria.   
Rifampicin resistance is a major problem for treatment of human infections by 
Staphyloccocus aureus and M. tuberculosis.  Many rifampicin-resistant clinical isolates 
of Staphyloccocus contain nonsynonymous single nucleotide substitutions that result 
amino acid substitutions in the rifampicin binding site (e.g. S455A, L466S, H481N) 
[Zhou et al., 2012; Murugan et al., 2015; Hellmark et al., 2009], but a three-nucleotide 
insertion mutant of rpoB has also been isolated [Hellmark et al., 2009].  A nine-
nucleotide deletion similar to the Δ9 mutant identified in our study may also generate a 
RIFR mutant, as the RNA polymerase β amino acid sequence corresponding to 506-
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FGSS-509 in E. coli is the same in S. aureus (Table 2).  A comparison of crystal 
structures of rifampicin bound to RNA polymerases of M. tuberculosis (MtrpoB) and E. 
coli (EcrpoB) indicates that rifampicin binds to highly conserved sites with nearly 
identical structures in both enzymes [Lin et al., 2017].  The most clinically important 
mutation in the treatment of tuberculosis, serine 450 (or 531 in E. coli) to leucine 
[Williams et al., 1998; Telenti et al., 1993], was not observed in our screen due to the 
codon encoding serine (TCT) requiring two mutations to mutate the residue to leucine.  
We did observe a similar S531F mutant, which required only a single mutation (TCC to 
TTC).  The Δ9 rifampicin resistant mutant in E. coli converts 506-FGSS-509 to C506.  
Homologous residues in  RNA polymerase β chains of 10 other bacteria are almost 
identical to E. coli RNA polymerase (Table 2).  A similar nine nucleotide deletion in 
MtrpoB would change the corresponding sequence to 425-SQLSQF-428  instead of 
CQLSQF in EcrpoB.  Serine and cysteine differ only by one atom (oxygen replaced by 
sulfur) and are chemically similar.  Thus, we hypothesize that a similar nine nucleotide 
deletion mutation may also confer resistance in M. tuberculosis and other bacteria.   
 
Materials and Methods 
Selection of RIFR strains of Escherichia coli.  E. coli K-12 MG1655 was streaked on 
Luria-Bertani Broth (LB)-agar plates to yield single colonies.  Colonies were picked and 
dissolved in 200 µl sterile saline.  10 µl of bacteria were diluted to individual cultures of 
25 ml of LB and shaken overnight at 37°C.  200 µl of each bacterial culture was plated on 
LB-agar plates containing 100 µg/mL rifampicin and cultured at 37°C overnight.  Plates 
generally contained between 5 and 250 colonies.  In addition, each individual 25 mL 
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culture was serially diluted to 10-5 or 10-6 and plated on LB-agar plates without 
antibiotics to determine the concentration of live bacteria in the culture. 
Sequencing of E. coli rpoB gene fragments form RifR strains.  Colonies were restreaked 
onto LB+rifampicin plates to obtain freshly grown bacteria.  Single colonies were picked 
and dissolved in 1X GoTaq Green Master Mix (Promega Corporation, Madison, 
Wisconsin) with 1 µM rpoBforward (5´- CGT GCG GTG AAA GAG CGT CTG TCT -
3´) and rpoBreverse (5´- ACG TTT AGC TAC CGC AGT TAC ACC -3´) primers.  The 
primers are designed to amplify nucleotides 1417-2160 of the E. coli K-12 MG1655 rpoB 
open reading frame.  The rpoB fragment was amplified directly from colonies with 30 
cycles of 95°C for 30 seconds, 57°C for 45 seconds, and 72°C for 1 minute after initial 
denaturation at 95°C for 2 minutes.  Polymerase chain reaction (PCR) amplification was 
confirmed by agarose gel electrophoresis.  PCR products were purified using the 
MinElute PCR Purification Kit (Qiagen Sciences, Germantown, Maryland) and 
sequenced by Sanger DNA sequencing using the rpoBforward primer (Genewiz, Inc., 
South Plainfield, New Jersey).   
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Table 1.  Mutations to rpoB gene identified from rifampicin-resistant E. coli. 
Residue number Protein sequence 
change 
Mutation* Number of 
observed clones 
506-509 FGSS to C 9 bp (1517-1525) 
deletion 
1 
512 S to Y TCT to TAT (1534) 1 
513 Q to K CAG to AAG (1537) 2 
 Q to L CAG to CTG (1538) 4 
 Q to P CAG to CCG (1538) 1 
516 D to Y GAC to TAC (1546) 3 
 D to N GAC to AAC (1546) 1 
 D to V GAC to GTC (1547) 11 
 D to G GAC to GGC (1547) 2 
526 H to Y CAC to TAC (1576) 29 
 H to N CAC to AAC (1576) 8 
 H to D CAC to GAC (1576) 1 
 H to L CAC to CTC (1577) 4 
531 S to F TCC to TTC (1592) 3 
572 I to F ATC to TTC (1714) 6 
 I to L ATC to CTC (1714) 1 
574 S to Y TCT to TAT (1721) 1 
* Nucleotide number in E. coli rpoB open reading frame in parentheses. 
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Table 2.  Protein sequence alignment of several bacterial RNA polymerases in RRDR I & 
II. 
Bacterial species rpoB residue RDRR I and II Protein sequence† 
Escherichia coli 505-533, 571-575 FFGSSQLSQFMDQNNPLSEITHKRRISAL LINSL 
Pseudomonas aeruginosa 508-538, 574-578 FFGSSQLSQFMDQNNPLSEITHKRRVSAL LINSL 
Neisseria meningitidis 527-557, 598-602 FFGSSQLSQFMDQTNPLSEVTHKRRVSAL LINSL 
Clostridioides difficile 479-509, 548-552 FFGSSQLSQFMDQTNPLSELTHKRRLSAL LINSL 
Streptococcus pneumoniae 475-505, 544-548 FFGSSQLSQFMDQHNPLSELSHKRRLSAL LINNL 
Staphylococcus aureus 459-488, 525-529 FFGSSQLSQFMDQANPLAELTHKRRLSAL LINSL 
Mycobacterium tuberculosis 422-452, 490-494 FFGTSQLSQFMDQNNPLSGLTHKRRLSAL LIGSL 
Mycobacterium smegmatis 419-449, 487-491 FFGTSQLSQFMDQNNPLSGLTHKRRLSAL LIGSL 
Chlamydia pneumoniae 448-478, 516-519 FFGRSQLSQFMDQTNPVAELTHKRRLSAL LITSL 
Thermus thermophilus 383-413, 451-455 FFSRSQLSQFKDETNPLSSLRHKRRISAL LITSL 
Thermus aquaticus 383-413, 451-455 FFSRSQLSQFKDETNPLSSLRHKRRISAL LITSL 
Sequence conservation‡  **: ****** *  **:  : ****:*** ** ** 
Mutations in this study   ----  ^^  ^         ^    ^    ^ ^ 
† Protein sequence shown in one-letter code.  Sequence corresponding with the ∆9 deletion mutation is 
shown in bold and denoted by dashes in the last row.  Point mutations observed in this study are denoted by 
^ in the last row. 
‡ Complete sequence identity amongst the RPOB sequences represented here denoted by “*”; Conservation 
of amino acid type (positively or negatively charged, hydrophobic, hydrophilic, side chain size) denoted by 
“:”. 
 
  
 13 
A 
 
B 
 
Figure 1.  Rifampicin binding to the bacterial transcriptional machinery.  (A) Rifampicin 
(yellow spheres) binds inside the DNA-RNA tunnel of RNA polymerase elongation 
complex (gray surface representation; 5UPC.pdb) to the surface of the β chain (cyan).  
The rifampicin binding site overlaps with the path of the nascent RNA chain (green).  
The template (red) and non-template (orange) DNA backbones are shown as lines, and 
the polymerase active site is shown as a magenta sphere.  (B) The rifampicin (Sticks 
representation; yellow carbons, blue nitrogens, red oxygens, white hydrogens) binding 
site (black box in (A)) and its solvent-exposed surface (gray) in E. coli RNA polymerase 
β chain (cyan) from 4KMU.pdb.  Locations of mutations identified in this study are 
depicted as magenta lines and labeled. 
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A      B 
 
C 
  
Figure 2.  The structure of the I-TASSER model of the Δ9 mutant.  (A) The Δ9 mutant 
model protein backbone (green lines connecting α-carbons) is superimposed on the 
crystal structure of rifampicin (pink lines) bound to the wild type E. coli RNA 
polymerase β chain (4KMU.pdb; gray ribbon).  Rifampicin is show in yellow sticks.  The 
red oval highlights the location of 506-FGSS-509 in the wild type RNA polymerase, 
which is mutated to C506 in the Δ9 mutant. (B) The Δ9 mutant (green lines connecting α-
carbons) is superimposed on the crystal structure of a DNA (blue)-RNA (brown) hybrid 
bound to the E. coli RNA polymerase transcriptional elongation complex (5UPC.pdb; 
pink lines). Residues 500-514 of the Δ9 mutant model are show in sticks. (C) 
Superimposition of rifampicin (sticks with yellow carbons) onto the Δ9 mutant model 
indicates steric clashes (red disks) with Q513, F514, and I572 (highlighted in red ovals).  
The side chain of Q513 forms a hydrogen bond (yellow dotted line) with the backbone 
carbonyl of Q510 (wild type numbering).  Figure 1B, 2A, 2B, and 2C are viewed in the 
same orientation.  Figures and clashes were generated in PyMol [DeLano, 2014]. 
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